

curriculum vitae

Michael Rudnicki, MD, FASN



Date of birth September 10th, 1973
Place of birth Warsaw, Poland
Nationality Austrian
Affiliation Medical University Innsbruck
 Dept. of Internal Medicine IV – Nephrology and Hypertension
 Anichstrasse 35
 6020 Innsbruck, Austria
Phone +43 512 504 81337 (office)
Email michael.rudnicki@i-med.ac.at
Homepage www.microarray.at

02-03/2012 Visiting scientist/clinician at the Dept. of Nephrology and Dialysis at the Ospedali Riuniti di Bergamo, Italy, Dir. Prof. Giuseppe Remuzzi

02/2010 FASN – Fellow of the American Society of Nephrology

12/2009 until present Senior Nephrologist (Oberarzt)

11/2009 Certification in Nephrology (Austria)

11/2007-10/2009 Nephrology fellow at the Dept. of Internal Medicine IV - Nephrology and Hypertension at the University Hospital Innsbruck/Medical University Innsbruck

11/2007 Certification in Internal Medicine (Austria)

10/2001-10/2007 Internal Medicine fellow at the Division of Nephrology and at the Dept. of Internal Medicine at the University Hospital Innsbruck/Medical University Innsbruck

08-09/2001 Post-doctoral fellow at the Div. of Nephrology, Innsbruck

10/1993-05/2001 Medical School at the University of Vienna, Austria

12/1994-02/1999 Technician at the research laboratories of the Div. of Nephrology at the University Hospital of Vienna

10/1993-07/1994 Civil service at the University Hospital of Vienna

1988-1993 Technical highschool, division of biochemistry, biotechnology and genetic engineering (*Höhere Technische Bundeslehr- und versuchsanstalt für Biochemie, biochemische Technologie und Gentechnik*), Vienna

1984-1988 Gymnasium (high-school), Vienna

Research experience

For detailed information of current research projects please visit www.mciroarray.at

Since 2010 Principal Investigator of the collaborative research project “PD-associated peritonitis – epidemiology and risk factors in Austrian centers”

Since 08/2009 Co-Investigator of the collaborative large scale integrating research project funded by the EU: Systems Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment (sysKID)

Since 08/2007 Co-Investigator of the research project funded by the Fonds zur Förderung der wissenschaftlichen Forschung (FWF) “*Functional significance of gene expression changes associated with renal ageing*”, started 08/2007

2002-2006 Supervising scientist of the research project funded by the Fonds zur Förderung der wissenschaftlichen Forschung (FWF) „*Gene expression pattern in renal tubular epithelial cells obtained from patients with kidney diseases*”

08-10/2001 Visiting scientist at Stanford University School of Medicine, Department of Nephrology, CA, USA. Main interest: “*Gene expression profiling using cDNA microarrays*”

1999-2001 MD-Thesis: “*VDJ-recombination, somatic hypermutation, polymerase μ and their potential relationship to the mechanism of chromosomal translocation in follicular lymphoma*”, group of Prof.U.Jaeger, Division of Hematology, University of Vienna

1994-1999 Technical research assistant, group Dr.G.Cohen, Division of Nephrology (head: Prof.W.H.Hörl), Department of Internal Medicine III, University of Vienna (*main research interest: isolation, characterisation and functional testing of uremic toxins from serum, HD-fluid and PD-fluid from uremic patients*)

Participation in sponsored studies

FIND-CKD: Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD

A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD)

The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy

The Effect of Sulodexide in Patients with Type 2 Diabetes and Microalbuminuria

Clinical experience

02-03/2012	Visiting clinician at the Dept. of Nephrology and Dialysis at the Ospedali Riuniti di Bergamo, Italy, Dir. Prof. Giuseppe Remuzzi; Main interest: <i>“Remission Clinic (Chronic Kidney Disease)”</i> and <i>“Rituximab in the treatment of nephrotic diseases such as Membranous Nephropathy, Minimal Change Disease and Focal-segmental Glomerulosclerosis”</i>
03/2011	ERA-EDTA Introductory Course in Epidemiology, Salzburg, Austria
2009 until present	Senior Nephrologist (Oberarzt)
2007-2009	Fellowship in Nephrology (Additivfacharzt für Nephrologie)
2001-2007	Fellowship in Internal Medicine (Facharzt für Innere Medizin)
03/2009	Nephrology 2009 course (Harvard Medical School, Boston, MA, USA)
09/2007	ERA-EDTA Introductory Course in Epidemiology, Leiden, the Netherlands
02/2005	Seminar on conducting phase III and IV clinical trials, Medical University Innsbruck, Austria
02/2003	CAPD course Amsterdam Medical University, the Netherlands
09/2002	European society of hypertension summer school, Glasgow, United Kingdom
	Special clinical interest: chronic kidney diseases and progression markers (biomarkers), nephrotic syndrome, hypertension, continuous ambulatory peritoneal dialysis, epidemiology

Teaching experience as tutor –Medical University Innsbruck

- Bedside teaching in Internal Medicine (students in the 5th and 6th year of medical school)
- Seminar in Evidence Based Medicine (students in 2nd year of medical school)
- Seminars in problem-based learning (PBL) in nephrology (students in 3rd year of medical school)
- Nephrology for dietitians and nurses

Memberships

- ÖGN – Österreichische Gesellschaft für Nephrologie (Austrian Society of Nephrology)

Österreichische Gesellschaft für Hypertensiologie (Austrian Society of Hypertension)
DGfN – Deutsche Gesellschaft für Nephrologie (German Society of Nephrology)
ASN - American Society of Nephrology (Fellow of the ASN)
ISN – International Society of Nephrology
ERA-EDTA – European Renal Association – European Dialysis and Transplant Association

Original manuscripts

Zitt E, König M, Vychytil A, Auinger M, Wallner M, Lingenhel G, Schilcher G, **Rudnicki M**, Salmhofer H, Lhotta K. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. *Nephrol. Dial. Transplant.* (2013) doi: 10.1093/ndt/gfs548

Poelzl G, Ess M, Von der Heide A, **Rudnicki M**, Frick M, Ulmer H. Concomitant renal and hepatic dysfunctions in chronic heart failure: Clinical implications and prognostic significance. *Eur J Intern Med.* 2012 Dec 21.

Kerschbaum J, König P, **Rudnicki M**. Risk Factors Associated with Peritoneal Dialysis-Related Peritonitis. *Int J Nephrol.* 2012;2012:483250. doi: 10.1155/2012/483250. Epub 2012 Dec 20.

Neuwirt H, Eder I, Pühr M, **Rudnicki M**. SOCS-3 is down-regulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/-3 independent manner. *Lab Invest.* 2013 Jan;93(1):123-34.

Rudnicki M, Perco P, Neuwirt H, Noppert SJ, Leierer J, Sunzenauer J, Eder S, Zoja C, Eller K, Rosenkranz AR, Müller GA, Mayer B, Mayer G. Increased Renal Versican Expression Is Associated With Progression of Chronic Kidney Disease. *PLoS One.* 2012;7(9):e44891.

Kirsch AH, Riegelbauer V, Tagwerker A, **Rudnicki M**, Rosenkranz AR, Eller K. The mTOR-inhibitor Rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. *Am J Physiol Renal Physiol.* 2012 Aug;303(4):F569-75.

Hellemons ME, Kerschbaum J, Bakker SJL, Neuwirt H, Mayer B, Mayer G, de Zeeuw D, Lambers Heerspink HJ, **Rudnicki M**. Validity of Biomarkers Predicting Onset or Progression of Nephropathy in Patients with Type 2 Diabetes: A Systematic Review. *Diabet Med.* 2012 May;29(5):567-77.

Neuwirt H, **Rudnicki M**, Schramek H, Mayer G. Monoclonal light chains and the kidney. *Nephrology Reviews* 2011 volume 3:e3

Noppert SJ, Eder S, **Rudnicki M**. Laser-Capture Microdissection of Renal Tubule Cells and Linear Amplification of RNA for Microarray Profiling and Real-Time PCR. *Methods Mol Biol.* 2011;755:257-66.

Kerschbaum J, König P, Hausdorfer J, Mayer G, **Rudnicki M**. Sevelamer use and incidence of peritonitis in peritoneal dialysis. *Wien Klin Wochenschr.* 2011 Mar 28.

Rudnicki M, Kerschbaum J, Hausdorfer J, Mayer G, Koenig P. Risk factors for peritoneal dialysis-associated peritonitis: The role of oral active vitamin D. *Perit Dial Int.* 2010 Sep;30(5):541-548.

Kopriva-Altfahrt G, König P, Mündle M, Prischl F, Roob JM, Wiesholzer M, Vychytil A; Austrian Study Group for Prevention of Peritoneal Catheter-Associated Infections, Arneitz K, Karner A, Artes R, Wolf E, Auinger M, Pawlak A, Fraberger J, Hofbauer S, Galvan G, Salmhofer H, Pichler B, Wazel M, Gruber M, Thonhofer A, Hager A, Malajner S, Heiss S, Braunsteiner T, Zweiffler M, König P, **Rudnicki M**, Kogler R, Kohlhauser D, Wiesinger T, Kopriva-Altfahrt G, Moser E, Kotanko P, Loibner H, Nitz H, Miska HJ, Wenzel R, Wölfer M, Mündle M, Breuss H, Hölzl B, Prischl F, Schmekal B, Riener EM, Roob JM, Wonisch W, Vikydal R, Vychytil A, Frank B, Wieser C, Wiesholzer M, Pokorny K. Exit-site care in Austrian peritoneal dialysis centers -- a nationwide survey. *Perit Dial Int*. 2009 May-Jun;29(3):330-9.

Schramek H, Sarközi R, Lauterberg C, Kronbichler A, Pirklbauer M, Albrecht R, Noppert SJ, Perco P, **Rudnicki M**, Strutz FM, Mayer G. Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells. *Lab Invest*. 2009 Sep 7.

Rudnicki M, Mayer G. Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. *Pharmacogenomics*. 2009 Mar;10(3):463-76.

Hochegger K, **Rudnicki M**, Auinger M, Mark W, Margreiter R, Mayer G, Rosenkranz AR. Fever of unknown origin in renal transplant patients with tacrolimus. *Clin Transplant*. 2009 Aug;23(4):575-9.

Rudnicki M, Perco P, Enrich J, Eder S, Heininger D, Bernthaler A, Wiesinger M, Sarközi R, Noppert SJ, Schramek H, Mayer B, Oberbauer R, Mayer G. Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. *Lab Invest*. 2009 Jan 12.

Sarközi R, Perco P, Hochegger K, Enrich J, Wiesinger M, Pirklbauer M, Eder S, **Rudnicki M**, Rosenkranz AR, Mayer B, Mayer G, Schramek H. Bortezomib-Induced Survival Signals and Genes in Human Proximal Tubular Cells. *J Pharmacol Exp Ther*. 2008 Dec;327(3):645-56.

Perco P, Wilflingseder J, Bernthaler A, Wiesinger M, **Rudnicki M**, Wimmer B, Mayer B, Oberbauer R. Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective. *J Cell Mol Med*. 2008 Aug;12(4):1177-87.

Hochegger K, Perco P, Enrich J, Mayer B, Mayer G, Rosenkranz AR, **Rudnicki M**. In vitro--transcriptional response of polymorphonuclear leukocytes following contact with different antigens. *Eur J Clin Invest*. 2007 Nov;37(11):860-9.

Rudnicki M, Eder S, Perco P, Enrich J, Scheiber K, Koppelstätter C, Schratzberger G, Mayer B, Oberbauer R, Meyer TW, Mayer G. Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. *Kidney Int*. 2007 Feb;71(4):325-35.

Rudnicki M, Eder S, Schratzberger G, Mayer B, Meyer TW, Tonko M, Mayer G. Reliability of t7-based mRNA linear amplification validated by gene expression analysis of human kidney cells using cDNA microarrays. *Nephron Exp Nephrol*. 2004;97(3):e86-95.

Cohen G, **Rudnicki M**, Deicher R, Hörl WH. Immunoglobulin light chains modulate polymorphonuclear leucocyte apoptosis. *Eur J Clin Invest*. 2003 Aug;33(8):669-76.

Rudnicki M, Mayer G. Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations. *Pharmacogenomics*. 2003 Mar;4(2):153-62.

Cohen G, **Rudnicki M**, Schmaldienst S, Hörl WH. Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients. *Nephrol Dial Transplant*. 2002 May;17(5):879-83.

Nadel B, Marculescu R, Le T, **Rudnicki M**, Böcskő S, Jäger U. Novel insights into the mechanism of t(14;18)(q32;q21) translocation in follicular lymphoma. *Leuk Lymphoma*. 2001 Nov-Dec;42(6):1181-94.

Cohen G, **Rudnicki M**, Walter F, Niwa T, Hörl WH. Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. *J Am Soc Nephrol*. 2001 Jun;12(6):1264-71.

Cohen G, **Rudnicki M**, Hörl WH. Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. *Kidney Int Suppl*. 2001 Feb;78:S48-52.

Cohen G, **Rudnicki M**, Hörl WH. Isolation of modified ubiquitin as a neutrophil chemotaxis inhibitor from uremic patients. *J Am Soc Nephrol*. 1998 Mar;9(3):451-6.

Cohen G, **Rudnicki M**, Hörl WH. A peptide isolated from a patient on continuous ambulatory peritoneal dialysis has homology to ubiquitin and inhibits the chemotactic response of polymorphonuclear leukocytes. *Miner Electrolyte Metab*. 1997;23(3-6):210-3.

Innsbruck, Austria

March 6th , 2013

Michael Rudnicki, MD, FASN